PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31

PURE BIOSCIENCE, INC.

Financials through Q3 FY2026, quarter ended Apr 30, 2026Last filing: 10-Q on Jun 15, 2026

$0.07−0.01 (-12.10%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2011 to 2025

59.3%+1.1 pts over 5 years

-103.4%−103.4 pts over 5 years

-109.1%−109.2 pts over 5 years

Per year	1 year	3 years	5 years	10 years	Five-year pace
Revenue	+12.4%	+6.6%	-20.5%	+11.7%
Gross profit	+13.1%	+9.2%	-20.2%	+11.4%

10 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2016	FY2020	FY2025
Return on equity	-388.1%	0.1%	60.1%
Return on assets	-265.6%	0.1%	-255.8%
Current ratio	2.42	3.68	1.12
Interest coverage	–	0.8×	-7.6×
Inventory turnover	1.6×	8.0×	9.1×
Capex to revenue	30.3%	0.8%	–
Diluted shares	57M	85M	112M

Return on equity split into margin, efficiency and leverage

Net margin-109.1%

Asset turnover2.34×

Equity multiplier-0.24×

Return on equity, FY202560.1%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2025	-109.1%	2.34×	-0.24×	60.1%
FY2024	-171.4%	1.48×	-1.02×	258.5%
FY2023	-211.7%	0.59×	1.51×	-189.5%
FY2022	-192.6%	0.41×	1.21×	-96.4%
FY2021	-62.7%	0.70×	1.30×	-56.9%
FY2020	0.1%	1.68×	1.38×	0.1%
FY2019	-343.3%	0.85×	1.82×	-530.5%
FY2018	-419.5%	0.55×	2.49×	-578.9%
FY2017	-342.1%	0.32×	1.80×	-198.4%
FY2016	-1114.9%	0.24×	1.46×	-388.1%

Parsed from the XBRL in Pure Bioscience's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-8 reverse split on Aug 15, 2012
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PURE.

Revenue growth26.8% · median 11.4%

Gross margin58.9% · median 40.0%

Operating margin-79.2% · median -343.6%

Net margin-91.2% · median -227.3%

Advertisement
300 × 250